Mr. Etienne Grima reports

CARDIOCOMM SOLUTIONS ANNOUNCES SUSPENSION OF TRADING BY THE TSX VENTURE EXCHANGE

On May 8, 2023, the TSX Venture Exchange suspended trading in Cardiocomm Solutions Inc.'s securities as a result of a cease trade order issued by the Ontario Securities Commission. The CTO was issued due to the corporation missing the deadline to file its annual financial statements for the financial year ended Dec. 31, 2022, and its management's discussion and analysis relating to the financial statements Filings") before the prescribed deadline of May 1, 2023 (see the company's press release dated May 2, 2023, for further details).

The required filings are anticipated to be filed by May 30, 2023, or sooner, following which the company will apply for reinstatement for trading on the TSX Venture Exchange. The company will provide updates as warranted.

About Cardiocomm Solutions Inc.

Cardiocomm's patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. Cardiocomm has earned the ISO 13485 certification, is HIPAA (Health Insurance Portability and Accountability Act) compliant, and holds clearances from the European Union (CE Mark), the United States (Food and Drug Administration) and Canada (Health Canada).

We seek Safe Harbor.